益气化痰法治疗老年晚期非小细胞肺癌的临床观察
|
摘要
目的
通过观察益气化痰法中药经验方对65岁以上老年晚期非小细胞肺癌治疗,能稳定瘤体、改善主要临床症状、提高患者生活质量的作用。益气化痰法中药与化疗联合治疗可以减轻化疗毒副反应,提高疗效。论证益气化痰法是治疗老年晚期非小细胞肺癌行之有效的重要方法。以丰富老年晚期肺癌的临床治疗手段,提高老年晚期非小细胞肺癌的临床疗效。
方法
将90例不宜或不愿意行手术、介入、放疗以及靶向治疗的老年晚期非小细胞肺癌患者分为中医组,中西医组,西医组每组各30例。中医组采用益气化痰法中药方包括：党参25g、茯苓25g,甘草6g、枳壳15g、天冬15g、猫爪草30g、枇杷叶15g、浙贝15g、仙鹤草15g、守宫5g。西医组,可按患者情况选用化疗GP、TP、DP、培美曲赛单药的方案。中西医组采用中医组治疗方案+西医组治疗方案,中西医结合进行治疗,各组分别治疗两个周期。主要观察指标为症状改善、生存质量和化疗中的毒副反应,其他指标为肿瘤缓解、KPS评分、CEA、体重变化等。
结果
三组患者主要临床症状的改善情况比较,中医与中西医组治疗前后主要症状积分比较减少明显,经统计处理有统计学意义(P<0.05)。西医组治疗前后主要症状积分比较减少无明显,无有统计学意义(P>0.05)。中医组与中西医组治疗前后在咳嗽、咳痰、血痰、气短、乏力、纳差的情况比较差异有统计学意义(P<0.05)。西医组治疗前后在咳嗽、咳痰、血痰、血痰、气短、乏力、纳差的情况比较差异无统计学意义(P>0.05)。说明中医组与中西医组对临床症状改善具较好的效果,中医组与中西医组优于西医组,特别在咳嗽、咳痰、血痰、气短、乏力、纳差方面。
三组患者瘤体变化情况比较,均未有病例达到CR,但有效率、稳定率中西医组最高(40%、76,6%),有效率西医组(11例占36,6%)所占比例高于中医组(1例占3.3%)但稳定率西医组(17例占56.7%)所占比例低于中医组(18例占60%)。三组治疗后肿瘤均缓解,差异有统计学意义(P<0.01),说明中药与化疗联合治疗后在肿瘤缓解情况最佳,中医组在缩小肿瘤方面不如西医组,但稳定瘤体方面有一定优势。
生存质量方面,三组治疗后,KPS评分均有一定程度的改善,其中中医组与中西医组优于西医组,三组在统计学上比较有统计学意义(P<0.05)。本研究是采用卡氏评分还是采用肺癌治疗功能评价表(FACT-L)来患者生存质量的变化均提示中医组与中西医组在身体状况、情绪状况、功能状况、附加关注状况治疗前后较明显改善,有统计学意义(P<0.05),西医组治疗前后较差异无统计学意义(P>0.05)。说明中药能改善患者身体状况和功能状况相关,通过改善身体状况及功能状况从而改善患者的情绪状况和肺癌特异性功能状况,提高患者生存质量。
三组治疗期间均在血液系统包括血红蛋白、白细胞、血小板降低比较差异均有显著性,经过统计分析(P<0.001),中医组基本无明显血液系统不良反应,中西医组的发生率显著低于西医组。三组在消化系统包括恶心呕吐、腹泻、肝功能毒副反应方面比较有显著性差异(P<0.05),其中中医组无发生毒副反应,中西医组毒副反应发生率低于西医组。在肾功能影响方面,中西医组不良反应发生率(13.33%)低于西医组不良反应发生率(20%)。研究的结果表明,中医药能减轻化疗毒副反应,有一定保护肝肾功能的作用。
中西医组治疗后比治疗前肿瘤指标(CEA)平均明显下降,经统计学有统计学意义(P<0.05)。中医与西医组治疗前后肿瘤指标(CEA)平均无明显下降,差异无统计学意义(P>0.05)。中西医组治疗后肿瘤指标(CEA)明显下降,符合中西医组稳定瘤体率和有效率最高。
三组治疗前患者体重平均比较差异无显著性意义(P>0.05),中医组与中西医组治疗后体重平均有明显增加,差异有统计学意义(P<0.05)。西医组治疗后体重平均明显下降,差异有统计学意义(P<0.05)
结论
(1)中医益气化痰法经验方能改善老年晚期NSCLC主要临床症状,特别在咳嗽、咳痰、血痰、气短、乏力方面尤为明显。
(2)中医益气化痰法经验方对晚期老年非小细胞肺癌患者具有稳定瘤体作用
(3)中医益气化痰法经验方可以明显提高患者生存质量与改善患者身体状况和功能状况,通过改善身体状况及功能状况从而改善患者的情绪状况和肺癌特异性功能状况,增加体重。
(4)中医益气化痰法经验方与化疗联合能提高化疗药物的治疗效果,减轻其毒副反应。
(5)益气化痰法是治疗老年晚期非小细胞肺癌行之有效的重要方法。
Objective:
Observation of the traditional Chinese medicines (TCM)"Device of Nourishing Qi and Eliminating Phlegm" therapy in patients of60years of age and above who are having non-small cell lung cancer at the last stage to figure out the impacts of the traditional medicines in preventing the development of tumors, improving major clinical symptoms in order to enhance the quality of life. The combination of the traditional Chinese medicines "device of Nourishing Qi and Eliminating" and chemotherapy can help reduce toxicity of the chemicals enhancing treatment effects. The therapy "Device of Nourishing Qi and Eliminating Phlegm" for the elderly having non-small cell lung cancer is an important and effective treatment that could contribute in enriching the clinical therapies for elderly patients having lung cancer at the last stage, improving clinical treatment effects on elderly having non-small cell lung cancer at the last stage
Method:
Ninety elderly patients with non-small cell lung cancer of the last stage who cannot or do not wish to undergo a surgery, vascular obstruction, or radiotherapy, targeted therapy are sampled for the research. The targeted therapy was broken in three groups including treatment of TCM (group Ⅰ), combination of treatment of TCM and chemotherapy (group Ⅱ), treatment of chemotherapy only (group Ⅲ). Each group involves30patients. Group Ⅰ receives treatment of traditional Chinese medicines "device of Nourishing Qi and Eliminating Phlegm" only. The ingredients include:Dangshen25g, Fuling25g, Gancao6g, Zhike15g, Tiandong15g, Maozhaocao30g, Pipayel5g, Zhebeimul5g, Xianhecaol5g, Shougong5g. Group Ⅲ:Platinum-based chemotherapy was used either TP, GP, DP and Almita single regimen. Group Ⅱ: the treatment of TCM is the same as that of group Ⅰ and chemotherapy is the same as that of group Ⅲ. The three groups all undergo two three-week treatment phases. The key indicators observed include (Ⅰ) improvement of the major symptoms,(Ⅱ) quality of lives,(Ⅲ) side effects of the chemicals during treatment, and other indicators such as reduction of the tumor sizes, KSP average, CEA, body weight changes, etc.
Results:
The comparison of improvement of the major symptoms among the three groups: shows significant symptom reduction in group Ⅰ and group Ⅱ (P<0.05). There is no clear reduction in the group Ⅲ in comparison between before and after since the results are not significant (P>0.05). Group Ⅰ and Group Ⅱ have remarkable improvement of the major symptoms and better than that of group Ⅲ, especially with the symptoms of coughing, sputum release, anhelation, tiredness, and eating less. The changes are statistically significant with (P<0.05). This proves that treatment of TCM clearly works well on improvement of the major symptoms.
Comparison of before and after treatment tumor changes among the three groups:There is no absolute elimination of tumor in any groups. Nevertheless, proportion of effective treatment (reduction of tumor sizes), proportion of stable tumor without any changes are highest in the group Ⅱ (40%and76.6%respectively). Proportion of effective treatment is higher in the group Ⅲ (11cases accounting for36.6%) than that of the group Ⅰ (1case accounting for3.3%). Nevertheless, proportion of patients with unchanged tumor sizes remains the same in the group Ⅲ (17cases accounting for56.7%), which is lower than that of the group Ⅰ (18cases accounting for60%). There tumor size changes are significant in all three groups (P<0.01). Apparently, combination of the TCM and chemotherapies has the most powerful impacts in tumor reduction. Traditional Chinese medicines only treatment helps prevent the tumor from getting larger.
Comparison of quality of lives after treatment among three groups:after treatment, KPS average increases in all three groups, of those group Ⅰ and group Ⅱ have clearer increase than group Ⅲ. The changes are significant in all three groups (P<0.05). This research, aside KPS average, employs a Functional Assessment of Cancer Threapy-Lung (FACT-L) to assess post-treatment changes in patients'quality of lives. The results show significant improvement in terms of physical situation, mental situation, functional situation, and other signs in the two group Ⅰ and group Ⅱ (P<0.05). There are no significant changes in group Ⅲ (P>0.05). This proves that TCM helps improve physical health and functions of the body so as improve emotional situation and abnormalities caused by lung cancers. Hence, it helps enhance the patients quality of lives. Comparison of side effects during treatment among three groups:there are decreases in numbers of platelets, leucocytes, erythrocytes, and hemoglobin, and the changes are significant in all three groups (P<0.001). Basically, there is no side effect of the serium system found in group Ⅰ, group Ⅱ has the lower proportion of side effects than groupⅢ. Side effects on the digestive system include vomiting, nausea, diarrhea, and liver functions are significantly different among three groups (P<0.05). Of those, no side effects observed in group Ⅰ, and group Ⅱ has lower proportion of side effects than does group Ⅲ. This indicates that the Traditional Chinese medicines help reduce side effects of the chemotherapy.
In group Ⅱ, comparison between before and after treatment shows significant decreases in CEA indicator(P<0.05). This is not the case for group Ⅰ and group Ⅲ while (P>0.05). The result of significant decrease of CEA indicator in group Ⅱ matches perfectly with the result of having highest proportion of patients with down-sized or undeveloped tumors in this group.
Before treatment, there are no significant changes in average body weight in all three groups. After treatment, there is significant increase in average body weight of the patients of group Ⅰ and Ⅱ (P<0.05). The average body weight of the patients of group Ⅲ is significantly decreased (P<0.05).
Conelusion:
(1) The device of Nourishing Qi and Eliminating Phlegm therapy (drawn from treatment experiences) that could clearly improve major symptoms of elderly patients having non-small cell lung cancer, especially for the symptoms such as coughing, sputum release, bloody sputum, anhelation, tiredness, and eating less.
(2)The device of Nourishing Qi and Eliminating Phlegm therapy (drawn from treatment experiences) inhibit (stabilize) the tumor development
(3)The device of Nourishing Qi and Eliminating Phlegm therapy (drawn from treatment experiences) enhance the quality of lives of patients and improve the physical and functional status so as improves emotional situation and abnormalities caused by lung cancers, and increases the body weight.
(4)The device of Nourishing Qi and Eliminating Phlegm therapy (drawn from treatment experiences) coupled with chemotherapy could enhance the treatment effects reducing the toxicity of the chemicals.
(5) Therefore, it is clear that device of Nourishing Qi and Eliminating Phlegm therapy appears to be an important and effective therapy for elderly patients having non-small cell lung cancer at the last stage.
通过观察益气化痰法中药经验方对65岁以上老年晚期非小细胞肺癌治疗,能稳定瘤体、改善主要临床症状、提高患者生活质量的作用。益气化痰法中药与化疗联合治疗可以减轻化疗毒副反应,提高疗效。论证益气化痰法是治疗老年晚期非小细胞肺癌行之有效的重要方法。以丰富老年晚期肺癌的临床治疗手段,提高老年晚期非小细胞肺癌的临床疗效。
方法
将90例不宜或不愿意行手术、介入、放疗以及靶向治疗的老年晚期非小细胞肺癌患者分为中医组,中西医组,西医组每组各30例。中医组采用益气化痰法中药方包括：党参25g、茯苓25g,甘草6g、枳壳15g、天冬15g、猫爪草30g、枇杷叶15g、浙贝15g、仙鹤草15g、守宫5g。西医组,可按患者情况选用化疗GP、TP、DP、培美曲赛单药的方案。中西医组采用中医组治疗方案+西医组治疗方案,中西医结合进行治疗,各组分别治疗两个周期。主要观察指标为症状改善、生存质量和化疗中的毒副反应,其他指标为肿瘤缓解、KPS评分、CEA、体重变化等。
结果
三组患者主要临床症状的改善情况比较,中医与中西医组治疗前后主要症状积分比较减少明显,经统计处理有统计学意义(P<0.05)。西医组治疗前后主要症状积分比较减少无明显,无有统计学意义(P>0.05)。中医组与中西医组治疗前后在咳嗽、咳痰、血痰、气短、乏力、纳差的情况比较差异有统计学意义(P<0.05)。西医组治疗前后在咳嗽、咳痰、血痰、血痰、气短、乏力、纳差的情况比较差异无统计学意义(P>0.05)。说明中医组与中西医组对临床症状改善具较好的效果,中医组与中西医组优于西医组,特别在咳嗽、咳痰、血痰、气短、乏力、纳差方面。
三组患者瘤体变化情况比较,均未有病例达到CR,但有效率、稳定率中西医组最高(40%、76,6%),有效率西医组(11例占36,6%)所占比例高于中医组(1例占3.3%)但稳定率西医组(17例占56.7%)所占比例低于中医组(18例占60%)。三组治疗后肿瘤均缓解,差异有统计学意义(P<0.01),说明中药与化疗联合治疗后在肿瘤缓解情况最佳,中医组在缩小肿瘤方面不如西医组,但稳定瘤体方面有一定优势。
生存质量方面,三组治疗后,KPS评分均有一定程度的改善,其中中医组与中西医组优于西医组,三组在统计学上比较有统计学意义(P<0.05)。本研究是采用卡氏评分还是采用肺癌治疗功能评价表(FACT-L)来患者生存质量的变化均提示中医组与中西医组在身体状况、情绪状况、功能状况、附加关注状况治疗前后较明显改善,有统计学意义(P<0.05),西医组治疗前后较差异无统计学意义(P>0.05)。说明中药能改善患者身体状况和功能状况相关,通过改善身体状况及功能状况从而改善患者的情绪状况和肺癌特异性功能状况,提高患者生存质量。
三组治疗期间均在血液系统包括血红蛋白、白细胞、血小板降低比较差异均有显著性,经过统计分析(P<0.001),中医组基本无明显血液系统不良反应,中西医组的发生率显著低于西医组。三组在消化系统包括恶心呕吐、腹泻、肝功能毒副反应方面比较有显著性差异(P<0.05),其中中医组无发生毒副反应,中西医组毒副反应发生率低于西医组。在肾功能影响方面,中西医组不良反应发生率(13.33%)低于西医组不良反应发生率(20%)。研究的结果表明,中医药能减轻化疗毒副反应,有一定保护肝肾功能的作用。
中西医组治疗后比治疗前肿瘤指标(CEA)平均明显下降,经统计学有统计学意义(P<0.05)。中医与西医组治疗前后肿瘤指标(CEA)平均无明显下降,差异无统计学意义(P>0.05)。中西医组治疗后肿瘤指标(CEA)明显下降,符合中西医组稳定瘤体率和有效率最高。
三组治疗前患者体重平均比较差异无显著性意义(P>0.05),中医组与中西医组治疗后体重平均有明显增加,差异有统计学意义(P<0.05)。西医组治疗后体重平均明显下降,差异有统计学意义(P<0.05)
结论
(1)中医益气化痰法经验方能改善老年晚期NSCLC主要临床症状,特别在咳嗽、咳痰、血痰、气短、乏力方面尤为明显。
(2)中医益气化痰法经验方对晚期老年非小细胞肺癌患者具有稳定瘤体作用
(3)中医益气化痰法经验方可以明显提高患者生存质量与改善患者身体状况和功能状况,通过改善身体状况及功能状况从而改善患者的情绪状况和肺癌特异性功能状况,增加体重。
(4)中医益气化痰法经验方与化疗联合能提高化疗药物的治疗效果,减轻其毒副反应。
(5)益气化痰法是治疗老年晚期非小细胞肺癌行之有效的重要方法。
Objective:
Observation of the traditional Chinese medicines (TCM)"Device of Nourishing Qi and Eliminating Phlegm" therapy in patients of60years of age and above who are having non-small cell lung cancer at the last stage to figure out the impacts of the traditional medicines in preventing the development of tumors, improving major clinical symptoms in order to enhance the quality of life. The combination of the traditional Chinese medicines "device of Nourishing Qi and Eliminating" and chemotherapy can help reduce toxicity of the chemicals enhancing treatment effects. The therapy "Device of Nourishing Qi and Eliminating Phlegm" for the elderly having non-small cell lung cancer is an important and effective treatment that could contribute in enriching the clinical therapies for elderly patients having lung cancer at the last stage, improving clinical treatment effects on elderly having non-small cell lung cancer at the last stage
Method:
Ninety elderly patients with non-small cell lung cancer of the last stage who cannot or do not wish to undergo a surgery, vascular obstruction, or radiotherapy, targeted therapy are sampled for the research. The targeted therapy was broken in three groups including treatment of TCM (group Ⅰ), combination of treatment of TCM and chemotherapy (group Ⅱ), treatment of chemotherapy only (group Ⅲ). Each group involves30patients. Group Ⅰ receives treatment of traditional Chinese medicines "device of Nourishing Qi and Eliminating Phlegm" only. The ingredients include:Dangshen25g, Fuling25g, Gancao6g, Zhike15g, Tiandong15g, Maozhaocao30g, Pipayel5g, Zhebeimul5g, Xianhecaol5g, Shougong5g. Group Ⅲ:Platinum-based chemotherapy was used either TP, GP, DP and Almita single regimen. Group Ⅱ: the treatment of TCM is the same as that of group Ⅰ and chemotherapy is the same as that of group Ⅲ. The three groups all undergo two three-week treatment phases. The key indicators observed include (Ⅰ) improvement of the major symptoms,(Ⅱ) quality of lives,(Ⅲ) side effects of the chemicals during treatment, and other indicators such as reduction of the tumor sizes, KSP average, CEA, body weight changes, etc.
Results:
The comparison of improvement of the major symptoms among the three groups: shows significant symptom reduction in group Ⅰ and group Ⅱ (P<0.05). There is no clear reduction in the group Ⅲ in comparison between before and after since the results are not significant (P>0.05). Group Ⅰ and Group Ⅱ have remarkable improvement of the major symptoms and better than that of group Ⅲ, especially with the symptoms of coughing, sputum release, anhelation, tiredness, and eating less. The changes are statistically significant with (P<0.05). This proves that treatment of TCM clearly works well on improvement of the major symptoms.
Comparison of before and after treatment tumor changes among the three groups:There is no absolute elimination of tumor in any groups. Nevertheless, proportion of effective treatment (reduction of tumor sizes), proportion of stable tumor without any changes are highest in the group Ⅱ (40%and76.6%respectively). Proportion of effective treatment is higher in the group Ⅲ (11cases accounting for36.6%) than that of the group Ⅰ (1case accounting for3.3%). Nevertheless, proportion of patients with unchanged tumor sizes remains the same in the group Ⅲ (17cases accounting for56.7%), which is lower than that of the group Ⅰ (18cases accounting for60%). There tumor size changes are significant in all three groups (P<0.01). Apparently, combination of the TCM and chemotherapies has the most powerful impacts in tumor reduction. Traditional Chinese medicines only treatment helps prevent the tumor from getting larger.
Comparison of quality of lives after treatment among three groups:after treatment, KPS average increases in all three groups, of those group Ⅰ and group Ⅱ have clearer increase than group Ⅲ. The changes are significant in all three groups (P<0.05). This research, aside KPS average, employs a Functional Assessment of Cancer Threapy-Lung (FACT-L) to assess post-treatment changes in patients'quality of lives. The results show significant improvement in terms of physical situation, mental situation, functional situation, and other signs in the two group Ⅰ and group Ⅱ (P<0.05). There are no significant changes in group Ⅲ (P>0.05). This proves that TCM helps improve physical health and functions of the body so as improve emotional situation and abnormalities caused by lung cancers. Hence, it helps enhance the patients quality of lives. Comparison of side effects during treatment among three groups:there are decreases in numbers of platelets, leucocytes, erythrocytes, and hemoglobin, and the changes are significant in all three groups (P<0.001). Basically, there is no side effect of the serium system found in group Ⅰ, group Ⅱ has the lower proportion of side effects than groupⅢ. Side effects on the digestive system include vomiting, nausea, diarrhea, and liver functions are significantly different among three groups (P<0.05). Of those, no side effects observed in group Ⅰ, and group Ⅱ has lower proportion of side effects than does group Ⅲ. This indicates that the Traditional Chinese medicines help reduce side effects of the chemotherapy.
In group Ⅱ, comparison between before and after treatment shows significant decreases in CEA indicator(P<0.05). This is not the case for group Ⅰ and group Ⅲ while (P>0.05). The result of significant decrease of CEA indicator in group Ⅱ matches perfectly with the result of having highest proportion of patients with down-sized or undeveloped tumors in this group.
Before treatment, there are no significant changes in average body weight in all three groups. After treatment, there is significant increase in average body weight of the patients of group Ⅰ and Ⅱ (P<0.05). The average body weight of the patients of group Ⅲ is significantly decreased (P<0.05).
Conelusion:
(1) The device of Nourishing Qi and Eliminating Phlegm therapy (drawn from treatment experiences) that could clearly improve major symptoms of elderly patients having non-small cell lung cancer, especially for the symptoms such as coughing, sputum release, bloody sputum, anhelation, tiredness, and eating less.
(2)The device of Nourishing Qi and Eliminating Phlegm therapy (drawn from treatment experiences) inhibit (stabilize) the tumor development
(3)The device of Nourishing Qi and Eliminating Phlegm therapy (drawn from treatment experiences) enhance the quality of lives of patients and improve the physical and functional status so as improves emotional situation and abnormalities caused by lung cancers, and increases the body weight.
(4)The device of Nourishing Qi and Eliminating Phlegm therapy (drawn from treatment experiences) coupled with chemotherapy could enhance the treatment effects reducing the toxicity of the chemicals.
(5) Therefore, it is clear that device of Nourishing Qi and Eliminating Phlegm therapy appears to be an important and effective therapy for elderly patients having non-small cell lung cancer at the last stage.
引文
[1]孙燕,石元凯.临床肿瘤内科手册[M].北京：人民卫生出版社,2007：388-416.
[2]Silveberg E, Lubera JA. Cancer statistics [J]. CA Cancer J Clin,1988,38:5-22.
[3]崔贤杰,多西他赛联合顺铂治疗Ⅲ、Ⅳ期非小细胞肺癌的临床观察[J].四川肿瘤防治,2006,19(3)：196-197.
[4]jemalA,SiegelR, Ward E, etal. Cancer statictics. CA CancerJ Clin 2009;59:225-249.
[5]万德森.临床肿瘤学[M],第二版.北京：科学出版社,2006：277-278.
[6]BUI CONG TOAN.TRAN VAN THUAN诊断和治疗肿瘤学[M].越南河内：医学出版社,2007：176.
[7]Parkin DM,BrayF,FerlayJ. Global cancer statistics[J]. CA Cancer JClin,2005,55:74-108.
[8]孙燕,周际昌.临床肿瘤内科手册[M].北京：人民卫生出版社,2003：264.
[9]李佩文.中西医临床肿瘤学[M].北京：中国中医药出版社,1996：611.
[10]廖美琳.肺癌[M].北京：中国医药科技出版社,2003：1.
[11]Scott Wj, HowingtonJ, FeigenbergS, etal. Treatment of non-small cell lung cancer stage Ⅰ and stage Ⅱ:ACCP evidence-based clinical practiceguidelines (2nd edition)Chest2007; 132:234S-242S.
[12]Pinon JP, Tribodet H, Scagliotti GV, et al. lung adjuvant cisplastin evaluation:a pooled analysis by the LACE Collaborative Group.J Clin Oncol 2008; 26:3552-3559.
[13]Robinson, LA, Ruckdeschel JC, Wagner H, Jr, etal. Treatment of non-small cell lung cancer-Stage ⅢA:ACCP Evidence-based Clinical Practice Guidelines (2nd Edition)Chest2007;132; 243S-265.
[14]Jett JR, Schild SE, Keith RL,etal. Treatment of non-small cell lung cancer, Stage ⅢB:ACCP Evidence-based Clinical Practice Guidelines (2nd Edition) Chest 2007; 132:266S-276.
[15]Albain KS, Swann RS, Rusch VR, etal. Phase Ⅲ study of concurrent chemmotherapy and radiotherapy(CT/RT) vs CT/RT followed by surgicalresection for stage ⅢA (pN2) non-small cell lung cancer(NSCLC):Outcomes update of North American Integroup 0139(RTOG 9309).J Clin Oncol 2005:23:7014.
[16]Schiller JH, Harrington D, Belani CP, etal. Comparision of four chemmotherapy Regimens fo avanced non- small cell lung cancer. N Engl J Med 2002;346:92-98.
[17]Sadler A, Gray R, Perry MC, etal. Paclitaxel-carboplatin aloneor with Bevacizumab for non- small cell lung cancer. NenglJ Med 2006; 355;2542-2550.
[18]Shepherd FA, Rodrigues PJ,Ciuleanu T, etal. Erlotinib in preyiously Treatment non- small cell lung cancer. N Engl J Med 2005;353:123-132.
[19]吴一龙.国外医学肿瘤学分册[J].1998,25：353-356.
[20]吴一龙主编.肺癌多学科综合治疗的理论与实践[M].北京：人民卫生出社,2001,
[2l]Hansen H, et al. Textbook of Lung cancer lsted. London, Martin Dunitz,2000:230.
[22]Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: ASouth west Oncology Group study[J]. Clin Oncol,1998,16:2459.
[23]Gatzemeier U, von Pawel J, Gottfried M, et al. Phase Ⅲ comparative study of high-dose cisplatin versus acombination of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer[J]. Clin Oncol,2000,18:3390.
[24]Sandler AB, Nemunaitis J, Denham C, et al. Phase Ⅲ trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer[J]. Clin Oncol,2000,18(1):122.
[25]SandlerAB, GrayR, Brahmer J, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer[J]. N Engl JMed,2006,355:2542-2550.
[26]Manegold C, Pawel J von, Zatloukal P, et al. Randomised, double blind multicentre phase Ⅲ study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapyna vepatients with advanced or recurrent non-squamous non-small cell, lung cancer(NSCLC):B017704[J]. Clin Oncol,2007,25(18s):7514.
[27]Shepherd FA. Seeond-Line chemotherapy fo non-small cell lung cancer. Expert Rev Anticancer Ther,2003,3:435-442.
[28]Leighl NB, Shepherd FA, Kwong R, et al. Economic analysis of the TAX 317 trial: docetaxel vesus best supportive care as second-Line therapy of advanced non-smallcell lung cancer[J]. clinoncal,2002,20:1341-352.
[29]Molina JR, Adjei AA. The role of pemetrexed (Alimta, LY231514) in lung cancertherapy[J]. Clin Lung Cancer,2003,5:21-27.
[30]Hanna N, ShePherd FA, Fossela FV, et al. Randomized Phase Ⅲ tral of Pemetrexed versus docetaxel in Patients with non-small cell lung cancer Previously treated wit chemotherapy[J]. clin Oncol,2004,22:1589-1597.
[31]Fukuoka M, Yano S, Giaccone G, etal. Multi institutional randomized phase Ⅱ trial of Gefitinib for previously treaded patients with aadvanced non small cell lung cancer [J]. Clinical,2003,21(12) 12237-2246.
[32]MillerVA, KrisMG, Shah N, et al. Bronchioloal veolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small cell lung cancer[J]. Clin Oncol,2004,22(6):1103-1109.
[33]Konishi J,Yamazaki K, Kinoshita I, et al. Analysis of the response and tox-icity to gefitinib of non-small cell lung cancer[J]. Anticancer Res,2005,25(1B):435-441.
[34]Birnbaum A, Ready N. Gefitinib therapy for non-small cell lung cancer[J]. Curr Treat Options Oncol,2005,6(1):75-81.
[35]Robert F. Blumenschein G, Dicke K. et al. Amulticenter phaseB/A study of antiepidermal growth factor receptor antibody cetuximab, incombination with gemcitaine/carboplatin in patients with advanced stagen on small cell lung cancer[J]. ProcASCO,2003:22643 (Abstr 2587).
[36]Hidalgo M. Siu LL, Nemunaitis J, et al. Phase and pharmacologic study of OSI2774, anepidermal growth factor receptor tyrosine kinase inhibitor, inpatient swith advanced solid malig nancies[J]. Clin Oncol,2001,19:3267.
[37]Clarke LE, Leitzel K, Smith J, et al. Epidermal growth factor receptor mRNA in peripheral blood of patients with pancreatic, lung, and colon carcinomas detected by RT-PCR [J]. Int Joncol.2003,22(2):4252-4301.
[38]廖美琳,赵家美.肺癌治疗概况[J].今日应用医学,1997,3(2)：8-9.
[39Pritchatd, R. and S. Anthony, chemotherapy plus radiotherapy compared whit radiotherapy onlone in the treatmen of locally advanced, unresectable, non-small-cell lung cancer[J]. Annals of internal medicine,1996,125 (9),723.
[40]李金瀚.非小细胞肺癌治疗的共识点、难点和亮点[J].中国肺癌杂志,2003(5)：344-346.
[41]王瑞萍.非小细胞肺癌中西医结合治疗[J].中华临床医药,2003,4(23)：45-47.
[42]张霆.肺癌之气血津液变化及证治探析[J].新中医,2007,39(4)：220-221.
[43]刘伟胜、冯维斌主编.中、西医肿瘤,呼吸病临床证证治,广东人民出版社。1999.31
[44]王正昌,刘嘉湘,等肺癌患者三种虚证类型的治疗生存期与血浆环核苷酸水平的关系,中西医结合杂志,1984,1(1)：23-25.
[45]刘嘉湘.辩证治疗原发性肺癌310例疗效分析[J].上海中医杂志,1985,10：3.
[46]宋俦,补气固元法对肿瘤化疗副作用疗效观察。天津中医,1993, (3)：24.
[47]张书林,行青椿,中医药治疗肺癌研究该概况及评述。中国中医药信息杂志,1998,5(1)：16.
[48]苗文红.中医辨证治疗肺癌89例报告[J].陕西肿瘤医学,2001,3(1)：59-60.
[49]许继平,裘维焰,等。益气养阴法与化疗对比治疗中晚期支气管肺癌生存率的追踪观察[J].江苏中医,1988, (12)：37.
[50]潘敏求,黎月恒,刘静安,等肺复方与化疗对照治疗中晚期原发性支气管肺鳞癌80例报道[J].中国中医药学报,1990,5(3)：19.
[51]顾伯文。猪苓多糖及其提取物(757)治疗肺癌的疗效[J].白求恩医科大学学报,1984,(1)：28.
[52]刘嘉湘,施志明,李和根,等.益肺抗瘤饮治疗271例非小细胞肺癌临床观察.上海中医药杂志,2001,(2)：4-6.
[53]郝建军,魏岳斌,刘志刚。益气养阴法为主治疗中晚期肺癌30例。实用中医内科杂志,2008(2)： 8.
[54]李金辉,李桂凤.益气活血解毒法配合化疗治疗非小细胞肺癌32例.中国中医急症,2005,14(9)：896-897.
[55]左明焕,胡凯文,陈信义.非小细胞肺癌患者手术前后中医证候特征研究[J].中医杂志,2002,43(8)：615-617.
[56]柴可群,王德玉.化痰祛瘀解毒法在肺癌治疗中的运用探讨[J].浙江中医杂志,2003,38(2)：254-256.
[57]陈玉琨.除痰化瘀法治肺癌的理论认识和临床应用[J].新中医,1993,25(1)：10.
[58]杨宗艳,林洪生,李道睿.单纯中药和单药化疗方案治疗老年晚期非小细胞肺癌的随机对照临床研究[S].第二届老年肿瘤学大会论文集,2007：190-193.
[59]张双胜,康莱特注射液治疗老年晚期非小细胞肺癌疗效观察[J].中国中西医结合杂志2001(2)9-7.
[60]刘城林,陈为平,崔书中,等.参芪扶正注射液辅助化疗治疗老年非小细胞肺癌临床观察[J].中国中西医结合杂志,2004,24(10)：901-903.
[61]周荣耀,钟惹,吴丽英等.健脾清肺汤联合化疗治疗老年非小细胞性肺癌的临床观察[S].第二届老年肿瘤学大会论文集,2007,353-358.
[62]周蓓.沙参麦冬汤加减对非小细胞肺癌化疗增效减毒的临床研究[J].新中医,20(4)：29-30.
[63]张汉祥,张忠法,刘洪.放疗加中药治疗老年性非小细胞肺癌一附48例报告[J].肿瘤防治杂志,2002,9(1)：83-84.
[64]田艳萍,王旗春.艾迪联合放疗治疗老年晚期非小细胞肺癌的疗效分析[J].中药药理与临床,2007,23(4)：57-58.
[65]石晓兰,范忠泽等,中西药结合介入治疗老年非小细胞肺癌的临床研究[J].上海中医药杂志.2001：11(12)：19-21.
[66]孙雪飞,陈景寒,孟龙等.康艾注射液在老年Ⅲ期非小细胞肺癌术前支气管动脉灌注新辅助化疗中的作用[J].中国老年学杂志,2006,(26)：734-735.
[67]刘兰芳,李青山,高东奇.槐耳颗粒对老年晚期非小细胞肺癌生活质量的影响[J].肿瘤学杂志,2006,12(1)：70-71.
[68]孙国胜.抗癌膏穴位贴敷治疗肺癌64例[J].辽宁中医杂志,2005,32(8)：794-795.
[69]陆惠化,方宁远,金玉华。实用老年医学[M].上海：上海科学技术出板社,2006,80-81.
[70]Ginsberg RJ, Hill LD, Eagan RT, et al. Modern thirty-day operative mortality for surgical resections in lung cancer[J].J Thorac Cardio-vasc Surg,1983,86(5):654-658.
[71]Wada H, Nakamura T, Nakamoto K, et al. Thirty-day operative mor-tality for thoracotomy in lung cancer [J].J Thorac Cardiovasc Surg,1998,115(1):70-73.
[72]Brock MV, Kim MP, Hooker CM, et al. Pulmonary resection in octo-genarians with stage I non small cell lung cancer:a 22year expecrience [J].Ann Thorac Surg,2004, 77(1):271-277
[73]方德康,汪良骏,张汝刚,等.青年人肺癌切除术的治疗结果(J).中国肿瘤临床,1999：26(6)：409-11.
[74]陈淑章,查建华,王峻峰,等.局限性肺切除在高龄肺癌治疗中的价值(J).东南国防医药,2008,10(2)：99-100.
[75]Gridelli C,Shepherd FA. Chemotherapy for elderly patients with non-small cell lung cancer:A review of the evidence[J]. Chest,2005,128(2):947-957.
[76]Gridelli C, AaproM, ArdizzoniA, et al. Treatment of advanced non-small-cell lung cancer in the elderly:Results of an international expert panel[j]. clin oncol,2005,23(13):3125-3137.
[77]Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of D6474, a smallmolecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epiderm al growth factor receptor tyrosine kinase[J]. Clin Cancer Res, 2003,9:1546-9.
[78]Jackman D, Yeap B, Lucca PA, et al. Phase Ⅱ study of erlotinib in elderly patients with previously untreated advanced non-small cell lung cancer (NSCLC):an analysis of quality of life and symptom response [J].JClin Oncol 2006,24:406.
[79]Pignon T, GregorA, Koning CS, et al. Age was no impaction acute and late toxicity of curative thoracic radiotherapy[J]. Radiother Oncol 1996,46:239-45.
[80]张海波,吴万垠,柴小姝,等.中药联合长春瑞滨治疗31例PS评分2.0的ⅢB/Ⅳ期非小细胞肺癌[J].上海中医药杂志,2006,40(7)：32.
[81]赵翠兰,李冉冉,徐妮.中西医结合治疗小细胞肺癌82例[J].菏泽医学专科学校学报,2005,17(3)： 49.
[82]Hurria A, Kris MG. Management of lung cancer in older adults [J]. CA cancer Jclin,2003, 53(6):325.
[83]梁业民,刘翠玲.青年肺癌及老年肺癌比较.四川肿瘤防治,1997, 0(4)：35-36.
[84]丁志远.青老年肺癌临床和病理特点的对比分析临床误诊误治[J]：12(4)：251-252
[85]Lichtman SM,Villani G. Chameotherapy in the elderly:pharmacologic Consideration[J]. Cancer Contron,2007,7(6):548-556.
[86]高学敏.中药学[M].北京：中国中医药出版社,2006：427.
[87]舒琦瑾,吴良村.新加沙参麦冬汤抗肿瘤的实验研究[J).中国中医基础医学杂志,2002,8(4)：34.
[88]Yamaki Metal. Planta Med.1989,55(2):169.
[89]刘春安,彭明.抗癌中草药大辞典[M].湖北：武汉湖北科技出版社,1994,958-959.
[90]陈锐深.现代中医肿瘤学[M].北京：人民卫生出版社.2003,188-189,371-372.
[91]陈锐深,曹洋.辨证化治肺癌132例分析[J].中医药学刊,2005,23(4)：593-594.
[92]黎壮伟.陈锐深治疗晚期肺癌长期存在1例[J].山东中医杂志,2005,24(3)：177.
[93]黎壮伟,陈志坚.陈锐深教授运用补脾法治疗恶性肿瘤经验介绍[J].新中医,2006,38(1)：16-17.
[94]史清华,曹洋.陈锐深治疗原发性支气管肺癌经验撷著[J].湖北中医杂志,2004,26(9)：20-21.
[2]Silveberg E, Lubera JA. Cancer statistics [J]. CA Cancer J Clin,1988,38:5-22.
[3]崔贤杰,多西他赛联合顺铂治疗Ⅲ、Ⅳ期非小细胞肺癌的临床观察[J].四川肿瘤防治,2006,19(3)：196-197.
[4]jemalA,SiegelR, Ward E, etal. Cancer statictics. CA CancerJ Clin 2009;59:225-249.
[5]万德森.临床肿瘤学[M],第二版.北京：科学出版社,2006：277-278.
[6]BUI CONG TOAN.TRAN VAN THUAN诊断和治疗肿瘤学[M].越南河内：医学出版社,2007：176.
[7]Parkin DM,BrayF,FerlayJ. Global cancer statistics[J]. CA Cancer JClin,2005,55:74-108.
[8]孙燕,周际昌.临床肿瘤内科手册[M].北京：人民卫生出版社,2003：264.
[9]李佩文.中西医临床肿瘤学[M].北京：中国中医药出版社,1996：611.
[10]廖美琳.肺癌[M].北京：中国医药科技出版社,2003：1.
[11]Scott Wj, HowingtonJ, FeigenbergS, etal. Treatment of non-small cell lung cancer stage Ⅰ and stage Ⅱ:ACCP evidence-based clinical practiceguidelines (2nd edition)Chest2007; 132:234S-242S.
[12]Pinon JP, Tribodet H, Scagliotti GV, et al. lung adjuvant cisplastin evaluation:a pooled analysis by the LACE Collaborative Group.J Clin Oncol 2008; 26:3552-3559.
[13]Robinson, LA, Ruckdeschel JC, Wagner H, Jr, etal. Treatment of non-small cell lung cancer-Stage ⅢA:ACCP Evidence-based Clinical Practice Guidelines (2nd Edition)Chest2007;132; 243S-265.
[14]Jett JR, Schild SE, Keith RL,etal. Treatment of non-small cell lung cancer, Stage ⅢB:ACCP Evidence-based Clinical Practice Guidelines (2nd Edition) Chest 2007; 132:266S-276.
[15]Albain KS, Swann RS, Rusch VR, etal. Phase Ⅲ study of concurrent chemmotherapy and radiotherapy(CT/RT) vs CT/RT followed by surgicalresection for stage ⅢA (pN2) non-small cell lung cancer(NSCLC):Outcomes update of North American Integroup 0139(RTOG 9309).J Clin Oncol 2005:23:7014.
[16]Schiller JH, Harrington D, Belani CP, etal. Comparision of four chemmotherapy Regimens fo avanced non- small cell lung cancer. N Engl J Med 2002;346:92-98.
[17]Sadler A, Gray R, Perry MC, etal. Paclitaxel-carboplatin aloneor with Bevacizumab for non- small cell lung cancer. NenglJ Med 2006; 355;2542-2550.
[18]Shepherd FA, Rodrigues PJ,Ciuleanu T, etal. Erlotinib in preyiously Treatment non- small cell lung cancer. N Engl J Med 2005;353:123-132.
[19]吴一龙.国外医学肿瘤学分册[J].1998,25：353-356.
[20]吴一龙主编.肺癌多学科综合治疗的理论与实践[M].北京：人民卫生出社,2001,
[2l]Hansen H, et al. Textbook of Lung cancer lsted. London, Martin Dunitz,2000:230.
[22]Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: ASouth west Oncology Group study[J]. Clin Oncol,1998,16:2459.
[23]Gatzemeier U, von Pawel J, Gottfried M, et al. Phase Ⅲ comparative study of high-dose cisplatin versus acombination of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer[J]. Clin Oncol,2000,18:3390.
[24]Sandler AB, Nemunaitis J, Denham C, et al. Phase Ⅲ trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer[J]. Clin Oncol,2000,18(1):122.
[25]SandlerAB, GrayR, Brahmer J, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer[J]. N Engl JMed,2006,355:2542-2550.
[26]Manegold C, Pawel J von, Zatloukal P, et al. Randomised, double blind multicentre phase Ⅲ study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapyna vepatients with advanced or recurrent non-squamous non-small cell, lung cancer(NSCLC):B017704[J]. Clin Oncol,2007,25(18s):7514.
[27]Shepherd FA. Seeond-Line chemotherapy fo non-small cell lung cancer. Expert Rev Anticancer Ther,2003,3:435-442.
[28]Leighl NB, Shepherd FA, Kwong R, et al. Economic analysis of the TAX 317 trial: docetaxel vesus best supportive care as second-Line therapy of advanced non-smallcell lung cancer[J]. clinoncal,2002,20:1341-352.
[29]Molina JR, Adjei AA. The role of pemetrexed (Alimta, LY231514) in lung cancertherapy[J]. Clin Lung Cancer,2003,5:21-27.
[30]Hanna N, ShePherd FA, Fossela FV, et al. Randomized Phase Ⅲ tral of Pemetrexed versus docetaxel in Patients with non-small cell lung cancer Previously treated wit chemotherapy[J]. clin Oncol,2004,22:1589-1597.
[31]Fukuoka M, Yano S, Giaccone G, etal. Multi institutional randomized phase Ⅱ trial of Gefitinib for previously treaded patients with aadvanced non small cell lung cancer [J]. Clinical,2003,21(12) 12237-2246.
[32]MillerVA, KrisMG, Shah N, et al. Bronchioloal veolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small cell lung cancer[J]. Clin Oncol,2004,22(6):1103-1109.
[33]Konishi J,Yamazaki K, Kinoshita I, et al. Analysis of the response and tox-icity to gefitinib of non-small cell lung cancer[J]. Anticancer Res,2005,25(1B):435-441.
[34]Birnbaum A, Ready N. Gefitinib therapy for non-small cell lung cancer[J]. Curr Treat Options Oncol,2005,6(1):75-81.
[35]Robert F. Blumenschein G, Dicke K. et al. Amulticenter phaseB/A study of antiepidermal growth factor receptor antibody cetuximab, incombination with gemcitaine/carboplatin in patients with advanced stagen on small cell lung cancer[J]. ProcASCO,2003:22643 (Abstr 2587).
[36]Hidalgo M. Siu LL, Nemunaitis J, et al. Phase and pharmacologic study of OSI2774, anepidermal growth factor receptor tyrosine kinase inhibitor, inpatient swith advanced solid malig nancies[J]. Clin Oncol,2001,19:3267.
[37]Clarke LE, Leitzel K, Smith J, et al. Epidermal growth factor receptor mRNA in peripheral blood of patients with pancreatic, lung, and colon carcinomas detected by RT-PCR [J]. Int Joncol.2003,22(2):4252-4301.
[38]廖美琳,赵家美.肺癌治疗概况[J].今日应用医学,1997,3(2)：8-9.
[39Pritchatd, R. and S. Anthony, chemotherapy plus radiotherapy compared whit radiotherapy onlone in the treatmen of locally advanced, unresectable, non-small-cell lung cancer[J]. Annals of internal medicine,1996,125 (9),723.
[40]李金瀚.非小细胞肺癌治疗的共识点、难点和亮点[J].中国肺癌杂志,2003(5)：344-346.
[41]王瑞萍.非小细胞肺癌中西医结合治疗[J].中华临床医药,2003,4(23)：45-47.
[42]张霆.肺癌之气血津液变化及证治探析[J].新中医,2007,39(4)：220-221.
[43]刘伟胜、冯维斌主编.中、西医肿瘤,呼吸病临床证证治,广东人民出版社。1999.31
[44]王正昌,刘嘉湘,等肺癌患者三种虚证类型的治疗生存期与血浆环核苷酸水平的关系,中西医结合杂志,1984,1(1)：23-25.
[45]刘嘉湘.辩证治疗原发性肺癌310例疗效分析[J].上海中医杂志,1985,10：3.
[46]宋俦,补气固元法对肿瘤化疗副作用疗效观察。天津中医,1993, (3)：24.
[47]张书林,行青椿,中医药治疗肺癌研究该概况及评述。中国中医药信息杂志,1998,5(1)：16.
[48]苗文红.中医辨证治疗肺癌89例报告[J].陕西肿瘤医学,2001,3(1)：59-60.
[49]许继平,裘维焰,等。益气养阴法与化疗对比治疗中晚期支气管肺癌生存率的追踪观察[J].江苏中医,1988, (12)：37.
[50]潘敏求,黎月恒,刘静安,等肺复方与化疗对照治疗中晚期原发性支气管肺鳞癌80例报道[J].中国中医药学报,1990,5(3)：19.
[51]顾伯文。猪苓多糖及其提取物(757)治疗肺癌的疗效[J].白求恩医科大学学报,1984,(1)：28.
[52]刘嘉湘,施志明,李和根,等.益肺抗瘤饮治疗271例非小细胞肺癌临床观察.上海中医药杂志,2001,(2)：4-6.
[53]郝建军,魏岳斌,刘志刚。益气养阴法为主治疗中晚期肺癌30例。实用中医内科杂志,2008(2)： 8.
[54]李金辉,李桂凤.益气活血解毒法配合化疗治疗非小细胞肺癌32例.中国中医急症,2005,14(9)：896-897.
[55]左明焕,胡凯文,陈信义.非小细胞肺癌患者手术前后中医证候特征研究[J].中医杂志,2002,43(8)：615-617.
[56]柴可群,王德玉.化痰祛瘀解毒法在肺癌治疗中的运用探讨[J].浙江中医杂志,2003,38(2)：254-256.
[57]陈玉琨.除痰化瘀法治肺癌的理论认识和临床应用[J].新中医,1993,25(1)：10.
[58]杨宗艳,林洪生,李道睿.单纯中药和单药化疗方案治疗老年晚期非小细胞肺癌的随机对照临床研究[S].第二届老年肿瘤学大会论文集,2007：190-193.
[59]张双胜,康莱特注射液治疗老年晚期非小细胞肺癌疗效观察[J].中国中西医结合杂志2001(2)9-7.
[60]刘城林,陈为平,崔书中,等.参芪扶正注射液辅助化疗治疗老年非小细胞肺癌临床观察[J].中国中西医结合杂志,2004,24(10)：901-903.
[61]周荣耀,钟惹,吴丽英等.健脾清肺汤联合化疗治疗老年非小细胞性肺癌的临床观察[S].第二届老年肿瘤学大会论文集,2007,353-358.
[62]周蓓.沙参麦冬汤加减对非小细胞肺癌化疗增效减毒的临床研究[J].新中医,20(4)：29-30.
[63]张汉祥,张忠法,刘洪.放疗加中药治疗老年性非小细胞肺癌一附48例报告[J].肿瘤防治杂志,2002,9(1)：83-84.
[64]田艳萍,王旗春.艾迪联合放疗治疗老年晚期非小细胞肺癌的疗效分析[J].中药药理与临床,2007,23(4)：57-58.
[65]石晓兰,范忠泽等,中西药结合介入治疗老年非小细胞肺癌的临床研究[J].上海中医药杂志.2001：11(12)：19-21.
[66]孙雪飞,陈景寒,孟龙等.康艾注射液在老年Ⅲ期非小细胞肺癌术前支气管动脉灌注新辅助化疗中的作用[J].中国老年学杂志,2006,(26)：734-735.
[67]刘兰芳,李青山,高东奇.槐耳颗粒对老年晚期非小细胞肺癌生活质量的影响[J].肿瘤学杂志,2006,12(1)：70-71.
[68]孙国胜.抗癌膏穴位贴敷治疗肺癌64例[J].辽宁中医杂志,2005,32(8)：794-795.
[69]陆惠化,方宁远,金玉华。实用老年医学[M].上海：上海科学技术出板社,2006,80-81.
[70]Ginsberg RJ, Hill LD, Eagan RT, et al. Modern thirty-day operative mortality for surgical resections in lung cancer[J].J Thorac Cardio-vasc Surg,1983,86(5):654-658.
[71]Wada H, Nakamura T, Nakamoto K, et al. Thirty-day operative mor-tality for thoracotomy in lung cancer [J].J Thorac Cardiovasc Surg,1998,115(1):70-73.
[72]Brock MV, Kim MP, Hooker CM, et al. Pulmonary resection in octo-genarians with stage I non small cell lung cancer:a 22year expecrience [J].Ann Thorac Surg,2004, 77(1):271-277
[73]方德康,汪良骏,张汝刚,等.青年人肺癌切除术的治疗结果(J).中国肿瘤临床,1999：26(6)：409-11.
[74]陈淑章,查建华,王峻峰,等.局限性肺切除在高龄肺癌治疗中的价值(J).东南国防医药,2008,10(2)：99-100.
[75]Gridelli C,Shepherd FA. Chemotherapy for elderly patients with non-small cell lung cancer:A review of the evidence[J]. Chest,2005,128(2):947-957.
[76]Gridelli C, AaproM, ArdizzoniA, et al. Treatment of advanced non-small-cell lung cancer in the elderly:Results of an international expert panel[j]. clin oncol,2005,23(13):3125-3137.
[77]Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of D6474, a smallmolecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epiderm al growth factor receptor tyrosine kinase[J]. Clin Cancer Res, 2003,9:1546-9.
[78]Jackman D, Yeap B, Lucca PA, et al. Phase Ⅱ study of erlotinib in elderly patients with previously untreated advanced non-small cell lung cancer (NSCLC):an analysis of quality of life and symptom response [J].JClin Oncol 2006,24:406.
[79]Pignon T, GregorA, Koning CS, et al. Age was no impaction acute and late toxicity of curative thoracic radiotherapy[J]. Radiother Oncol 1996,46:239-45.
[80]张海波,吴万垠,柴小姝,等.中药联合长春瑞滨治疗31例PS评分2.0的ⅢB/Ⅳ期非小细胞肺癌[J].上海中医药杂志,2006,40(7)：32.
[81]赵翠兰,李冉冉,徐妮.中西医结合治疗小细胞肺癌82例[J].菏泽医学专科学校学报,2005,17(3)： 49.
[82]Hurria A, Kris MG. Management of lung cancer in older adults [J]. CA cancer Jclin,2003, 53(6):325.
[83]梁业民,刘翠玲.青年肺癌及老年肺癌比较.四川肿瘤防治,1997, 0(4)：35-36.
[84]丁志远.青老年肺癌临床和病理特点的对比分析临床误诊误治[J]：12(4)：251-252
[85]Lichtman SM,Villani G. Chameotherapy in the elderly:pharmacologic Consideration[J]. Cancer Contron,2007,7(6):548-556.
[86]高学敏.中药学[M].北京：中国中医药出版社,2006：427.
[87]舒琦瑾,吴良村.新加沙参麦冬汤抗肿瘤的实验研究[J).中国中医基础医学杂志,2002,8(4)：34.
[88]Yamaki Metal. Planta Med.1989,55(2):169.
[89]刘春安,彭明.抗癌中草药大辞典[M].湖北：武汉湖北科技出版社,1994,958-959.
[90]陈锐深.现代中医肿瘤学[M].北京：人民卫生出版社.2003,188-189,371-372.
[91]陈锐深,曹洋.辨证化治肺癌132例分析[J].中医药学刊,2005,23(4)：593-594.
[92]黎壮伟.陈锐深治疗晚期肺癌长期存在1例[J].山东中医杂志,2005,24(3)：177.
[93]黎壮伟,陈志坚.陈锐深教授运用补脾法治疗恶性肿瘤经验介绍[J].新中医,2006,38(1)：16-17.
[94]史清华,曹洋.陈锐深治疗原发性支气管肺癌经验撷著[J].湖北中医杂志,2004,26(9)：20-21.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |